Sean Ross, Ph.D.
Sean Ross, Ph.D.
Senior Scientist II
AbbVie
Enabling chemistry at the interface of late discovery and early development
At AbbVie, the process chemistry group works in collaboration with our discovery and product development science and technology groups to develop active pharmaceutical ingredients (API) from their discovery to market. Critical early deliveries of API to enable preclinical studies requires the development of enabling routes to accelerate drug development. This talk will describe the rapid development of an enabling route to a preclinical target across discovery and process chemistry. The focus of the talk will include the development of a cross electrophile coupling approach to install a key C-C bond, as well as the development of a C-O cross coupling to form the penultimate intermediate This collaborative effort successfully delivered API that was supported a wide range of pre-clinical studies.
Sean Ross
Sean began his formal chemistry education at the University of Nevada, Reno where he obtained his B.S. in chemistry. During this time, he performed undergraduate research with Professor Bob Sheridan on the matrix isolation of carbenes, and with Professor Mazal on the synthesis of 1.1.1 propellanes. This later led him to pursue a Ph.D. in organic chemistry from the University of Minnesota. At the University of Minnesota, Sean joined the lab of Professor Tom Hoye working on the development of methodologies utilizing thermally generated benzynes. After defending his Ph.D. in 2011, Dr. Ross moved to the University of Utah where he joined the group of Professor Matt Sigman. There he worked on applying data science techniques to the redox-relay Heck reaction. In 2021, Sean joined AbbVie as a part of the Process Chemistry team. His current work is focused on the development of enabling chemistry to facilitate the kilo-scale manufacture of active pharmaceutical ingredients for late preclinical and early clinical studies.
Hosted by Professor Christopher Douglas
Sponsored by AbbVie
